Joseph Jimenez has been guiding big pharma Novartis through the business labyrinth for seven years. Under his leadership, the company went through cost-cutting restructurings that rendered fine results. However, Jimenez resigned from his position. He is going to hand over the reins to American doctor Vasant Narasimhan early next year. Therefore, the Harvard-trained professional will be the new head of the $48 billion-worth pharma company Novartis.
Narasimhan to Be the New CEO of Pharma Company Novartis as of February 1, 2018
Narasimhan is currently global chief of drug development and chief medical officer at Novartis. However, on February 1 the expert is going to climb up the career ladder as the new CEO of the Swiss pharmaceutical company. Joseph Jimenez created this window of opportunity by resigning from his position on his own accord. Jimenez claimed that seven years as a CEO is enough for him. He is now ready to return to the U.S. with his family.
Narasimhan is an internal choice as the new leader of the big pharma company. Harvard-instructed doctor joined the corporation in 2005. Since then, he successfully carried out a large selection of attributions and leadership positions within the company. On top of his Harvard medical degree, he also received a Harvard master’s degree in public policy and bachelor’s degree in biological sciences from the University of Chicago.
Jimenez Was a Mentor to Narasimhan
Novartis delivered the news on Monday through a public statement. Representatives claimed that Jimenez would continue to support the company he served through words of advice and support until August 31, 2018.
On top of that, Narasimhan worked for Jimenez and received guidance from his mentor. Therefore, he is already familiar with the ruling business. As a consequence, Novartis is expecting a smooth transition with no major disruptions along the way. The 41-year-old future CEO will be the youngest leader within the global pharmaceutical companies.
Image source: 1